Label: LUTERA- levonorgestrel and ethinyl estradiol kit

  • NDC Code(s): 75907-079-28, 75907-079-55
  • Packager: Dr. Reddy's Laboratories Inc.
  • Category: HUMAN PRESCRIPTION DRUG LABEL
  • DEA Schedule: None
  • Marketing Status: Abbreviated New Drug Application

Drug Label Information

Updated September 20, 2024

If you are a consumer or patient please visit this version.

  • SPL UNCLASSIFIED SECTION
    Rx only - Patients should be counseled that this product does not protect against HIV infection (AIDS) and other sexually transmitted diseases (STDs) such as chlamydia, genital herpes, genital ...
  • DESCRIPTION
    Each active, white tablet (21) contains 0.1 mg of levonorgestrel, d (-)-13β-ethyl-17α-ethinyl-17β- hydroxygon-4-en-3-one, a totally synthetic progestogen, and 0.02 mg of ethinyl estradiol ...
  • CLINICAL PHARMACOLOGY
    Mode of Action - Combination oral contraceptives act by suppression of gonadotropins. Although the primary mechanism of this action is inhibition of ovulation, other alterations include changes ...
  • INDICATIONS AND USAGE
    Lutera is indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. Oral contraceptives are highly effective. Table II lists the typical ...
  • CONTRAINDICATIONS
    Lutera is contraindicated in females who are known to have or develop the following conditions: Thrombophlebitis or thromboembolic disorders - A history of deep-vein thrombophlebitis or ...
  • WARNINGS
    Cigarette smoking increases the risk of serious cardiovascular side effects from oral-contraceptive use. This risk increases with age and with the extent of smoking (in epidemiologic studies ...
  • PRECAUTIONS
    1. General - Patients should be counseled that oral contraceptives do not protect against transmission of HIV (AIDS) and other sexually transmitted diseases (STDs) such as chlamydia, genital ...
  • ADVERSE REACTIONS
    Post Marketing Experience - Five studies that compared breast cancer risk between ever-users (current or past use) of COCs and never-users of COCs reported no association between ever use of COCs ...
  • OVERDOSAGE
    Symptoms of oral contraceptive overdosage in adults and children may include nausea, vomiting, and drowsiness/fatigue; withdrawal bleeding may occur in females. There is no specific antidote and ...
  • NONCONTRACEPTIVE HEALTH BENEFITS
    The following noncontraceptive health benefits related to the use of oral contraceptives are supported by epidemiological studies which largely utilized oral contraceptive formulations containing ...
  • DOSAGE AND ADMINISTRATION
    To achieve maximum contraceptive effectiveness, Lutera® (levonorgestrel and ethinyl estradiol tablets) must be taken exactly as directed and at intervals not exceeding 24 hours. The dosage of ...
  • HOW SUPPLIED
    Lutera® tablets (0.1 mg levonorgestrel and 0.02 mg ethinyl estradiol) are available in a 28 Tablet Dispenser (75907-079-28), arranged in 3 rows of 7 active tablets and 1 row of inert tablets, as ...
  • Brief Summary Patient Package Insert
    This product (like all oral contraceptives) is intended to prevent pregnancy. Oral contraceptives do not protect against transmission of HIV (AIDS) and other sexually transmitted diseases (STDs ...
  • DETAILED PATIENT LABELING
    This product (like all oral contraceptives) is intended to prevent pregnancy. Oral contraceptives do not protect against HIV (AIDS) and other sexually transmitted diseases (STDs) such as ...
  • PRINCIPAL DISPLAY PANEL - Kit Carton
    NDC 75907-079-55 - Lutera - ® Levonorgestrel and Ethinyl Estradiol - Tablets USP - 28-DAY REGIMEN - Each white tablet (21) contains 0.1 mg levonorgestrel and 0.02 mg ethinyl - estradiol. Each ...
  • INGREDIENTS AND APPEARANCE
    Product Information